Profiling cancer genemutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing

Oncologist

Volumn 19, Issue 4, 2014, Pages 336-343

  Zhang, Liangxuan ^a   Chen, Liangjing ^b   Sah, Sachin ^b   Latham, Gary J ^b   Patel, Rajesh ^a   Song, Qinghua ^a   Koeppen, Hartmut ^a   Tam, Rachel ^a   Schleifman, Erica ^a   Mashhedi, Haider ^a   Chalasani, Sreedevi ^a   Fu, Ling ^a   Sumiyoshi, Teiko ^a   Raja, Rajiv ^a   Forrest, William ^a   Hampton, Garret M ^a   Lackner, Mark R ^a   Hegde, Priti ^a   Jia, Shidong ^a  

^a GENENTECH INC   (United States)

^b ASURAGEN INC   (United States)

Author keywords

Ampliseq; Ion torrent; Molecular diagnostics; Mutation; Next generation sequencing; Precision oncology

Indexed keywords

FORMALDEHYDE; GENOMIC DNA; PARAFFIN; DNA; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN;

AMPLISEQ; ARTICLE; BIOINFORMATICS; CANCER CELL CULTURE; CLINICAL EVALUATION; COLORECTAL TUMOR; COMPARATIVE MOLECULAR FIELD ANALYSIS; CONTROLLED STUDY; DNA EXTRACTION; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; MOLECULAR DIAGNOSIS; NEXT GENERATION SEQUENCING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TUMOR GENE; COLORECTAL NEOPLASMS; DNA SEQUENCE; GENETIC VARIABILITY; GENETICS; HIGH THROUGHPUT SEQUENCING; HISTOLOGY; MUTATION; NUCLEOTIDE SEQUENCE; PROCEDURES; TISSUE FIXATION; TUMOR CELL LINE;

BASE SEQUENCE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FORMALDEHYDE; GENES, NEOPLASM; GENETIC VARIATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; PARAFFIN; PHOSPHATIDYLINOSITOL 3-KINASES; SEQUENCE ANALYSIS, DNA; TISSUE EMBEDDING; TISSUE FIXATION;

EID: 84898464134     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0180     Document Type: Article

References (25)

1. Meldrum C, Doyle MA, Tothill RW. Nextgeneration sequencing for cancer diagnostics: A practical perspective. Clin Biochem Rev 2011;32: 177-195.
2. Beadling C, Neff TL, Heinrich MC et al. Combining highly multiplexed PCR with semiconductorbased sequencing for rapid cancer genotyping. JMol Diagn 2013;15:171-176.
3. Singh RR, Patel KP, Routbort MJ et al. Clinical validation of a next-generation sequencing screen formutational hotspots in 46 cancer-related genes. J Mol Diagn 2013;15:607-622.
4. Next-generation screening goes national in UK. Cancer Discov 2013;3:OF6.
5. Jia S, Liu Z, Zhang S et al. Essential roles of PI(3)Kp110beta in cell growth, metabolism and tumorigenesis. Nature 2008;454:776-779.
6. Hadd AG, Houghton J, Choudhary A et al. Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffinembedded and fine-needle aspiration tumor specimens. J Mol Diagn 2013;15:234-247.
7. Patel R, Tsan A, Tam R et al. Mutation scanning using MUT-MAP, a high-throughput, microfluidic chip-based, multi-analyte panel. PLoS One 2012;7: e51153.
8. Jia S, Gao X, Lee SH et al. Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov 2013;3: 44-51.
9. Tang X, Boxer M, Drummond A et al. A germline mutation in KIT in familial diffuse cutaneous mastocytosis. J Med Genet 2004;41:e88.
10. Lee JH, Han SU, Cho H et al. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 2000;19:4947-4953.
11. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-337.
12. Wood LD, Parsons DW, Jones S et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-1113.
13. Rodon J, Dienstmann R, Serra V et al. Development of PI3K inhibitors: Lessons learned from early clinical trials. Nat Rev Clin Oncol 2013;10: 143-153.
14. Lackner MR. Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways. Expert Rev Mol Diagn 2010;10:75-87.
15. Jia S, Roberts TM, Zhao JJ. Should individual PI3 kinase isoformsbetargetedin cancer? Curr Opin Cell Biol 2009;21:199-208.
16. She QB, Chandarlapaty S, Ye Q et al. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One 2008;3:e3065.
17. Spoerke JM, O'Brien C, Huw L et al. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res 2012;18: 6771-6783.
18. Zhang J, Roberts TM, Shivdasani RA. Targeting PI3K signaling as a therapeutic approach for colorectal cancer. Gastroenterology 2011;141:50-61.
19. Quail MA, Smith M, Coupland P et al. A tale of three next generation sequencing platforms: Comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genomics 2012; 13:341.
20. Ilić N, Roberts TM. Comparing the roles of the p110a and p110b isoforms of PI3K in signaling and cancer. Curr Top Microbiol Immunol 2010;347: 55-77.
21. Kurose K, Gilley K, Matsumoto S et al. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet 2002;32: 355-357.
22. Gandara DR, Li T, Lara PN Jr. et al. Algorithm for codevelopment of new drug-predictive biomarker combinations: Accounting for inter- and intrapatient tumor heterogeneity. Clin Lung Cancer 2012; 13:321-325.
23. Liu Y, Hegde P, Zhang F et al. Prostate cancer-A biomarker perspective. Front Endocrinol (Lausanne) 2012;3:72.
24. Yan M, Liu QQ. Targeted therapy: Tailoring cancer treatment. Chin J Cancer 2013;32:363-364.
25. Aggarwal S. Targeted cancer therapies. NatRev Drug Discov 2010;9:427-428.